CSOP China Healthcare Disruption Index ETF
(HKD Counter Stock Code: 3174)

IMPORTANT INFORMATION about the CSOP China Healthcare Disruption Index ETF

IMPORTANT: Investment involves risks. Investment value may rise or fall. Past performance information presented is not indicative of future performance. Investors should refer to the Prospectus and the Product Key Facts Statement for further details, including product features and risk factors. Investors should not base on this website alone to make investment decisions.

The CSOP China Healthcare Disruption Index ETF (the “Sub-Fund”) is a sub-fund of the CSOP ETF Series OFC (“Company”), which is a public umbrella open-ended fund company established under Hong Kong law with variable capital with limited liability and segregated liability between sub-funds. The Sub-Fund is a passively managed index tracking ETF authorised under Chapter 8.6 of the Code on Unit Trusts and Mutual Funds. The shares of the Sub-Fund (the “Shares”) are traded on the Stock Exchange of Hong Kong Limited (the “SEHK”) like stocks.

SFC registration and authorization do not represent a recommendation or endorsement of the Company or the Sub-Fund nor do they guarantee the commercial merits of the Company or the Sub-Fund or their performance. They do not mean the Company or the Sub-Fund is suitable for all investors nor do they represent an endorsement of its suitability for any particular investor or class of investors.

The Sub-Fund is a physical ETF and invests primarily in Hong Kong listed companies that have business operations in various innovative fields such as biotechnology and biopharmaceuticals in the healthcare sector in mainland China, Hong Kong, Taiwan and Macau. The Sub-Fund is denominated in HKD.

The Sub-Fund is not principal guaranteed and your investments may suffer losses. There is no assurance that the Sub-Fund will achieve its investment objective.
The Sub-Fund’s investment in equity securities is subject to general market risks, whose value may fluctuate due to various factors, such as changes in investment sentiment, political and economic conditions and issuer-specific factors.
Solactive China Healthcare Disruption Index (the “Index”) is a new index. The Sub-Fund may be riskier than other exchange traded funds tracking more established indices with longer operating history.
The investments of the Sub-Fund are concentrated in the disruption/innovative healthcare sector. The value of the Sub-Fund may be more volatile than that of a fund having a more diverse portfolio of investments and companies that adopt more traditional business models.
The economic prospects of the healthcare sector are generally subject to greater influences from governmental policies and regulations than those of many other industries. Certain health care companies may allocate greater than usual financial resources to research and product development and experience above-average price movements associated with the perceived prospects of success of the research and development programs. In addition, certain healthcare companies may be adversely affected by lack of commercial acceptance of a new product or process or by technological change and obsolescence.
Investing in companies in the innovative fields in the healthcare sector will subject to additional risks such as regulatory risks, financial risks and new business risks similar to the risks associated with biotech companies. Companies pursuing disruptive innovation may be less profitable at the outset and the Sub-Fund may suffer losses by investing in them.
All these may have an impact on the business and/or profitability of the healthcare companies in which the Sub-Fund invests and therefore may adversely affect the NAV of the Sub-Fund.
The investments of the Sub-Fund in the healthcare sector may include biotech companies. Biotech companies invest heavily in research and development which may not necessarily lead to commercially successful products, and the ability for biotech companies to obtain regulatory approval (for example, product approval) may be long and costly. In addition, the prospects of biotech companies may significantly be impacted by technological changes, increased governmental regulations and intense competition from competitors.
Many biotech companies are also dependent upon the ability to use and enforce intellectual property rights and patents, and any such impairment may have adverse financial consequences.
Biotech companies may incur net current liabilities which may expose the company to the risk of shortfalls in liquidity, prices may be more volatile than the overall market and would require the company to seek adequate financing such as external debt. Any difficulty or failure of a biotech company to meet its liquidity needs as and when needed may have a material adverse effect on its business, financial condition, results of operations and prospects.
Biotech companies invested by the Sub-Fund may be pre-revenue companies with limited track record or operating history, unlike other listed companies with longer track record or operating history. Pre-revenue companies refer to companies which have yet to generate any sales revenue typically because they do not have any products on the market yet. Pre-revenue companies are subject to a higher degree of risk generally and they have a higher risk of failure when compared to other companies. Valuations of pre-revenue companies are also subject to a high risk of being inaccurate. The Sub-Fund’s investments in these companies will be subject to higher investment risks.
Biotech companies may not be able to generate any profits during the development stage of its products or at all. Even if a biotech company is able to generate revenue in a short run, it may not become profitable on a sustainable basis or at all.
All these may have an impact on the business and/or profitability of the biotech companies in which the Sub-Fund invests and therefore may adversely affect the NAV of the Sub-Fund.
The investments of the Sub-Fund in the healthcare sector may also include pharmaceutical and medical devices companies. Pharmaceutical and medical devices companies are heavily dependent on patent protection. The expiration of patents may adversely affect the profitability of the companies. Many new products are subject to regulatory approval, the process of which can be long and costly and approved products are susceptible to obsolescence. Certain pharmaceutical and medical devices companies may allocate greater than usual financial resources to research and product development and experience above-average price movements associated with the perceived prospects of success of the research and development programs. Pharmaceutical and medical devices companies are also subject to heavy competitive forces that may make it difficult to raise prices. All these may have impact on the business and/or profitability of pharmaceutical and medical devices companies in which the Sub-Fund invests and therefore may adversely affect the NAV of the Sub-Fund.
The Index is subject to concentration risk as a result of tracking the performance of companies active in the innovative fields in the healthcare sector. This may result in greater volatility in the value of the Sub-Fund than more diverse portfolios which comprise broad-based investments.
The Index is subject to geographical concentration risks as a result of tracking the performance of primarily Hong Kong listed companies that have business operations in the field of healthcare sector in mainland China, Hong Kong, Taiwan and Macau. The value of the Sub-Fund may be more susceptible to adverse economic, political, policy, foreign exchange, liquidity, tax, legal or regulatory event affecting the Hong Kong market and places where these companies have business operations including mainland China, Taiwan and Macau.
Risks associated with FDIs include counterparty/credit risk, liquidity risk, valuation risk, volatility risk and over-the-counter transaction risk. FDIs are susceptible to price fluctuations and higher volatility, and may have large bid and offer spreads and no active secondary markets. The leverage element/component of an FDI can result in a loss significantly greater than the amount invested in the FDI by the Sub-Fund. Exposure to FDIs may lead to a high risk of significant loss by the Sub-Fund.
Securities lending transactions may involve the risk that the borrower may fail to return the securities lent out in a timely manner and the value of the collateral may fall below the value of the securities lent out.
Although the Manager will use its best endeavours to put in place arrangements so that at least one market maker will maintain a market for the Shares and that at least one market maker gives not less than 3 months’ notice prior to terminating market making arrangement under the relevant market maker agreement, liquidity in the market for the Shares may be adversely affected if there is no or only one market maker for the Shares. There is also no guarantee that any market making activity will be effective.
The Sub-Fund may be subject to tracking error risk, which is the risk that its performance may not track that of the Index exactly. This tracking error may result from the investment strategy used, and fees and expenses. The Manager will monitor and seek to manage such risk in minimising tracking error. There can be no assurance of exact or identical replication at any time of the performance of the Index.
The trading price of the Shares on the SEHK is driven by market factors such as the demand and supply of the Shares. Therefore, the Shares may trade at a substantial premium or discount to the Sub-Fund’s NAV.
As investors will pay certain charges (e.g. trading fees and brokerage fees) to buy or sell Shares on the SEHK, investors may pay more than the NAV per Share when buying Shares on the SEHK, and may receive less than the NAV per Share when selling Shares on the SEHK.
The Sub-Fund may be terminated early under certain circumstances, for example, where the Index is no longer available for benchmarking or if the size of the Sub-Fund falls below USD10,000,000 (or its equivalent in the Sub-Fund’s base currency). Investors may not be able to recover their investments and suffer a loss when the Sub-Fund is terminated.
Payment of dividends out of capital or effectively out of capital amounts to a return or withdrawal of part of an investor’s original investment or from any capital gains attributable to that original investment. Any such distributions involving payment of dividends out of capital or effectively out of capital of the Sub-Fund may result in an immediate reduction of the NAV per Share of the Sub-Fund.
The Sub-Fund is passively managed and the manager will not have the discretion to adapt to market changes due to the inherent investment nature of the Sub-Fund. Falls in the index are expected to result in corresponding falls in the value of the Sub-Fund.

Please note that the above listed investment risks are not exhaustive and investors should read the Prospectus and the Product Key Facts Statement in detail before making any investment decision.

Investment Objective and Investment Strategy

The investment objective of the CSOP China Healthcare Disruption Index ETF (the “Sub-Fund”) is to provide investment results that, before deduction of fees and expenses, closely correspond to the performance of the Index, namely, Solactive China Healthcare Disruption Index (the “Index”).
The Sub-Fund is a physical ETF and invests primarily in Hong Kong listed companies that have business operations in various innovative fields in the healthcare sector in mainland China, Hong Kong, Taiwan and Macau. The Sub-Fund is denominated in HKD. In order to achieve the investment objective, the Sub-Fund primarily uses a physical representative sampling strategy.*

* Please refer to the section “Investment Strategy” of Prospectus for an explanation on the strategy

Product Features

A key product of CSOP thematic ETFs to envisage the future of investments
Comprehensive investments, covering representative healthcare-related leaders in Greater China
Primarily employing physical representative sampling strategy to replicate the performance of the Index
Capturing innovative growth potential of Greater China’s healthcare industry development

Intra-day Estimated NAV 1 & Market Price 2

Market Information 3, 4

  Date Last Change Change (%)
NAV per Share in HKD - - - -
Closing Price in HKD - - - -

Fund Information

SEHK Listing Date 21 July 2021
Financial Year 31 December
Asset Class Equity
Domicile Hong Kong
Total NAV -
Outstanding Units -
Management Fee (All in) ^ 0.99% per annum
Ongoing Charges Over A Year # Estimated to be 1.5%
Base Currency HKD
Number of Holdings -

^ Include custodian fee, registrar fee and administration fee. Please note that some fees may be increased up to a permitted maximum amount by providing one month’s prior notice to Shareholders. Please refer to the section headed “Fees and Charges” in Part 1 of the Prospectus for details.

# The ongoing charges figure is based on expenses for the year ended 31 December 2019. This figure may vary from year to year. It represents the ongoing expenses chargeable to the Sub-Fund expressed as a percentage of the Sub-Fund’s average NAV.

Underlying Index Information

Underlying Index Solactive China Healthcare Disruption Index
Index Provider Solactive AG
Currency HKD
Benchmark Level Type Net Total Return Free Float Market Capitalisation Weighted
Bloomberg Ticker SOLCHCDN
Reuters Code .SOLCHCDN

Trading Information

  HKD Traded Unit
Exchange Hong Kong Stock Exchange – Main Board
Date of Listing / Dealing 21 July 2021
Primary Exchange Time Zone GMT+8
Exchange Ticker 3174
Bloomberg Ticker 3174 HK
ISIN HK0000756202
Trading Board Lot 100 Shares
Trading Currency HKD

Participating Dealers 5

Haitong International Securities Company LimitedChina International Capital Corporation Hong Kong Securities Limited
Valuable Capital LimitedSG Securities (HK) Limited
Huatai Financial Holdings (Hong Kong) LimitedGoldman Sachs (Asia) Securities Limited
Citigroup Global Markets Asia LimitedMirae Asset Securities (HK) Limited
  • The near real time indicative NAV per Share in HKD (updated every 15 seconds during SEHK trading hours) is indicative and for reference purposes only.
  • Market prices are provided on a 15-minute delayed basis by ICE.
  • Change of the closing price in HKD indicates change of closing price since previous SEHK trading day. (Source: Bloomberg)
  • The last NAV per Share in HKD is indicative and for reference purpose only.
  • Additional Participating Dealer(s) will be appointed from time to time.
  • Please refer to HKEX website for the most updated information. Additional Market Maker(s) will be appointed from time to time.

Performance

  1 Month 3 Month 6 Month Year to date Since Inception#
CSOP China Healthcare Disruption Index ETF*
Solactive China Healthcare Disruption Index**

* Where no figure is shown there was insufficient data available.

** Performance of Index is based on total return.

# Cumulative performance is calculated since the inception date on 20 July 2021.

Accumulative performance of the Sub-Fund will be presented only after 6 months from its launch.

All dollar amounts are in HKD and all dates are in GMT+8 Time, unless otherwise specified.

Performance is calculated on NAV to NAV basis in HKD with dividend reinvested, taking into account ongoing charges and excluding your trading costs on SEHK.

Past performance information is not indicative of future performance. Investors may not get back the full amount invested.

These figures show by how much the fund increased or decreased in value during the period being shown.

Tracking Difference/ Error

Tracking Difference (TD)

Tracking difference is the return difference between an ETF and its underlying benchmark/ index over a certain period of time.

Tracking Error (TE)

Tracking error measures how consistently an ETF follows its benchmark/ index. It is the volatility (measured by standard deviation) of that return difference.
Tracking Difference Tracking Error
As of 31 August, 2021
Fund Listing Date: 21 July, 2021
Estimated Annual TD: -2.0%
Rolling 1-Year TD: N/A
Since Inception: -0.09%
As of 31 August, 2021
Fund Listing Date: 21 July, 2021
No TE data will be displayed during the first year of listing

Graph for Tracking Difference

Sub-Fund’s performance is calculated on an NAV to NAV basis and assumes reinvestment of distributions.

Holdings

Total Net Asset Value (in HKD) Number of Securities 1 Securities (%) 2
- - -

As of 24 Sep, 2021

Sectors Breakdown

As of 24 Sep, 2021

All Holdings

  • Sort by
Total records: 35

All dollar amounts are in HKD. All dates are in GMT+8 Time. Any exceptions are noted.

1. The "Number of Securities" represents the number of underlying securities held by the Sub-Fund.
2. May include dividends booked but not yet received.
3. In accordance with the Prospectus of CSOP ETF Series OFC, the Manager may in consultation with the Custodian, having regard to relevant circumstances, adjust the value of any investment of the Sub-Fund so as to reflect the fair value of the investment.
Total allocation percentages shown in All Holdings table may not equal 100% due to rounding or omissions of holdings of less than 1%. Information on certain fund holdings of less than 1% may not be widely available and hence may not be included in the table of holdings shown.

Important information about payment of distributions out of capital or effectively out of capital

The Manager may, at its discretion make distributions out of capital. The Manager may also, at its discretion, make distributions out of gross income while all or part of the fees and expenses of a Sub-Fund are charged to/paid out of the capital of the Sub-Fund, resulting in an increase in distributable income for the payment of distributions by the Sub-Fund and therefore, the Sub-Fund may effectively pay distributions out of the capital.
Investor should note that payment of distributions out of capital or effectively out of capital amounts to a return or withdrawal of part of an investor’s original investment or from any capital gains attributable to that original investment. Any distributions involving payment of distributions out of or effectively out of the Sub-Fund’s capital may result in an immediate reduction of the Net Asset Value per Share. The Manager may amend its distribution policy subject to the SFC’s prior approval and by giving not less than one month’s prior notice to Shareholders.

Distribution History

Ex-Date Record Date Payable Date Dividend Per Share Dividend Paid Out of Net Distributable Income* for the month Dividend Paid Out of Capital

*“Net distributable income” means the net investment income (i.e. dividend income and interest income net of fees and expenses) attributable to the relevant share class and may also include net realised gains (if any) based on unaudited management accounts. However, “net distributable income” does not include net unrealised gains.

The data in “dividend paid out of net distributable income” and “dividend paid of out of capital” are just for reference only. Please refer to the official distribution information in the dividend per share column.

Warning: Please note that a positive distribution yield does not imply a positive return. Investors should not make any investment decision solely based on information contained in the table above. There is no guarantee of distribution. Investors should read the relevant offering document (including the key facts statement) of the fund for further details including the risk factors.

All dollar amounts are in HKD. All dates are in GMT+8 Time. Any exceptions are noted.

Disclaimer:

This website is owned and managed by CSOP Asset Management Limited (“CSOP”). CSOP reserves the right to change, modify, add or delete, any content and the terms & conditions of use of this website without notice. Users are advised to periodically review the contents of this website to be familiar with any modifications.

The performance figures contained on this website are for informational purposes only. Past performance is not indicative of future performance. Investment involves risks and the Sub-Fund's NAV per share may rise as well as fall. Persons interested in investing in the Sub-Fund should read the relevant fund offering documents (including the full text of the risk factors stated therein) in detail before making any investment decision.

This website is prepared by CSOP and has not been reviewed by the Securities and Futures Commission.


Index Provider Disclaimer:

CSOP China Healthcare Disruption Index ETF is not sponsored, promoted, sold or supported in any other manner by Solactive AG nor does Solactive AG offer any express or implicit guarantee or assurance either with regard to the results of using the Solactive China Healthcare Disruption Index and/or the use of Solactive trade mark or the index price/prices of the Solactive China Healthcare Disruption Index at any time or in any other respect. The Solactive China Healthcare Disruption Index is calculated and published by Solactive AG. Solactive AG uses its best efforts to ensure that the Solactive China Healthcare Disruption Index is calculated correctly. Irrespective of its obligations towards CSOP Asset Management Limited, Solactive AG has no obligation to point out errors in the Solactive China Healthcare Disruption Index to third parties including but not limited to investors and/or financial intermediaries of the CSOP China Healthcare Disruption Index ETF. Neither publication of the Solactive China Healthcare Disruption Index by Solactive AG nor the licensing of the Solactive China Healthcare Disruption Index or Solactive trade mark for the purpose of use in connection with the CSOP China Healthcare Disruption Index ETF constitutes a recommendation by Solactive AG to invest capital in the CSOP China Healthcare Disruption Index ETF nor does it in any way represent an assurance or opinion of Solactive AG with regard to any investment in the CSOP China Healthcare Disruption Index ETF. Remember, the information in this Prospectus does not constitute tax, legal or investment advice and is not intended as a recommendation for buying or selling securities. The information and opinions contained in this Prospectus have been obtained from public sources believed to be reliable, but no representation or warranty, express or implied, is made that such information is accurate or complete and it should not be relied upon as such. Solactive AG will not be responsible for the consequences of reliance upon any opinion or statement contained herein or for any omission.


Data Provider Disclaimer:

IOPV calculations and delayed market data as shown on CSOP website (the “data”) provided by ICE Data Indices, see ICE Terms of Use, and is updated during HK Exchange trading hours. Powered by Factset. IOPV is indicative and for reference purposes only. The Sub-Fund is not sponsored, endorsed, sold or marketed by ICE Data Indices, LLC, its affiliates (“ICE Data”) and ICE Data or its respective third party suppliers make no express or implied warranties, and hereby expressly disclaim all warranties of merchantability or fitness for a particular purpose with respect to the iNAV, IOPV, fund or any fund data included therein. In no event shall ICE Data have any liability for any special, punitive, direct, indirect, or consequential damages (including lost profits), even if notified of the possibility of such damages. You acknowledge that the data is provided for information only and should not be relied upon for any purpose. HKEX Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

工作機會暫時只提供於英語版本, 請前往英語頁面繼續操作

前往工作機會

Privacy Statement

This is the website of CSOP Asset Management Limited ("CSOP"). We understand that our customers and website visitors are concerned about the privacy of information. We have established policies and procedures concerning the collection, use and security of your information that will help protect your privacy. This policy statement provides information on the obligations and policies of CSOP under the Personal Data (Privacy) Ordinance (the "Ordinance").

OUR CORPORATE POLICY

CSOP recognize the importance of personal data to our business and the importance of respecting the privacy rights of our clients. Therefore, we are committed to ensuring compliance with the requirements of the Ordinance. Each employee of CSOP must abide by our commitment to privacy in the handling of personal information. To further enhance confidentiality and security of all personal data, only authorized staff will be allowed to have access to the personal information collected. It is restricted to those persons who have a business need to access personal information in order to perform their job duties.

The purpose of this Statement is to establish the policies and practices of CSOP's commitment to protect the privacy of personal data and to inform you about our responsibilities and your rights under the Ordinance.

Types of Personal Data Held

There are two broad categories of personal data held by us. They are personal data relating to clients and employees of CSOP.

Personal data held by us regarding clients may include the following:-

Personal data relating to employment held by us may include the following:-

Main Purposes of keeping Personal Data

The purposes for which personal data relating to clients may be used are as follows:-

The purposes for which personal data relating to employees may be used are as follows:-

Transfer of Personal Data

Personal data held by CSOP relating to clients will be kept confidential but may be transferred to the following parties (whether within or outside the Hong Kong Special Administrative Region) for any of the purposes stated above:-

Accuracy of Personal Data

CSOP strive at all times to ensure accuracy of all personal data collected and processed by us. In order to assist us to deliver on this pledge, please inform us immediately in the event that your personal information has been changed or you discovered that your personal information held by us is incorrect.

Your Rights

It is not a statutory requirement for you to provide personal data to us. However, we will not be able to provide you with the services and products you may require unless you provide us with the necessary personal data or information.

You have a right (i) to be informed whether we hold any of your personal data; (ii) to be supplied with a copy of your personal data we hold; and (iii) to request correction of your personal data we hold. If you wish to access to and/or to correct any of your personal data held by us, please send your written request to the address set out below. We may, subject to the Ordinance, impose a reasonable fee for complying with a data access request.

If you do not wish your personal data to be used for direct marketing purposes, you may notify us in writing to the following address:-

Head of Legal & Compliance

CSOP Asset Management Limited,
2801-2802 Two Exchange Square
8 Connaught Place, Central
Hong Kong

Upon receipt of such notice, we shall, without charge to you, cease using your personal data for direct marketing purposes.

Disclaimer

CSOP Asset Management Limited ("CSOP") is a regulated institution in Hong Kong by the Securities and Futures Commission (“SFC”). This website contains information about CSOP and the services and products offered by CSOP. The information provided on the CSOP website is not intended for distribution to, or use by, any person or entity in any jurisdiction or country that would subject CSOP or its affiliates to any registration requirement within such jurisdiction or country. Non-Hong Kong investors are responsible for observing all applicable laws and regulations of their relevant jurisdictions before proceeding to access the information contained herein. By proceeding, you are representing that you have understood and accepted the restrictions set out in this section.

The website is prepared by CSOP and has not been reviewed by the SFC. You are advised to exercise caution and if you are in any doubt about any of the contents of the website, you should obtain independent financial and professional advice. Private Investors are advised to consult with their financial advisors, banks, or other professional advisors. Nothing herein should be construed as investment advice nor as comment on the suitability of any investment or investment service. Prospective investors should take advice from their own professional advisors before making any investment decision.

The information contained in this website is provided for reference only and does not constitute any investment advice. Past performance is not an indicative of future performance. Investment involves risk and investors may not get back the amount originally invested. Please read the relevant offering document carefully, in particular fund features and the risks involved in investing in the fund.

Nothing on this website constitutes a solicitation, invitation, recommendation or offer to purchase a product offered by CSOP or any CSOP funds or as the basis for any investment decision.

This site may include forward-looking statements which are based on CSOP's current opinions, expectations and projections. CSOP undertake no obligation to update or revise any forward-looking statements. Actual results could differ materially from those anticipated in the forward-looking statements.

If you have accessed this site using a link from another site, CSOP do not accept any liability or responsibility for the accuracy of information contained within the sites of other providers who have links to any pages of this site.

CSOP do not accept responsibility for any interference or damage to your own computer system, the records stored therein or those of any other person, which arises in connection with your use of this website or any linked website. A Cookies is utilized on this website. It allows your browser to check whether you have read and agreed to these terms. The Cookies does not contain any personally identifiable information. Unfortunately, if your browser is set up to reject Cookies you will not be able to see the content of this website. All copyrights reserved and its contents including all information, graphics, code, text and design in this website are owned by CSOP and should not be reproduced or distributed without its permission. These terms are governed exclusively by the laws of Hong Kong and constitute the entire agreement between you and CSOP in relation to the use of this website.

The information is current as at the date of publication but is subject to change without notice.

Please input email address

Wrong email address